IP Library Granted Patent US 10,597,710
Granted Patent B2
US 10,597,710 · App. 14/839,433 · Granted Mar 24, 2020

Ligase activity

Inventors: Gregory Lohman (Cambridge, MA); Thomas C. Evans, Jr. (Topsfield, MA); Larry A. McReynolds (Beverly, MA)
Assignee: New England Biolabs, Inc.
C12Q1/6862C12N9/93C12Q1/6853C12Y605/01003G01N2333/9015
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,597,710
App. No.
14/839,433
Granted
Mar 24, 2020
Kind
B2
Abstract

Compositions and methods are provided for ligating polynucleotides having a length that is greater than 8 nucleotides on an RNA splint. The ligation reaction provides consistent results in high or low ATP concentrations. The reaction can occur rapidly and is generally at least 10 fold more efficient than T4DNA ligase under optimal conditions for T4DNA ligase and the reaction time is less than 6 hours for example, less than 1 hour.

Claims (19)

1. A method for detecting a polymorphism in an RNA, comprising:

(a) hybridizing at least two DNA polynucleotide sequences to a polymorphic sequence in an RNA;

(b) ligating the at least two DNA polynucleotide sequences to one another using a ligase that has an amino acid sequence that is at least 90% identical to the Chlorella virus PBCV-1 ligase of SEQ ID NO:1, to produce a ligation product, and

(c) detecting the ligation product of (b), thereby detecting the polymorphic sequence.

2. The method of claim 1 , wherein the RNA is of biological origin.

3. The method of claim 1 , wherein the RNA is the genome of an RNA virus.

4. The method of claim 1 , wherein the RNA is a cellular RNA.

5. The method of claim 4 , wherein the cellular RNA is a miRNA, long non-coding RNA, mRNA or tRNA.

6. The method of claim 1 , wherein the ligation of step (b) is a done in a buffer comprising 1 μM to 1.5 mM ATP.

7. The method of claim 1 , wherein the RNA has a length of at least 10 nucleotides.

8. The method of claim 1 , wherein the ligation product of step (b) is circular.

9. The method of claim 1 , wherein the ligation product of step (b) is linear.

10. The method of claim 1 , wherein the ligase is PBCV-1 ligase.

11. The method of claim 1 , wherein the detecting step (c) comprises amplifying the ligation product of step (b).

12. The method of claim 11 , wherein the amplifying is done by PCR.

13. The method of claim 11 , wherein the amplifying is done by rolling circle amplification.

14. The method of claim 1 , wherein the RNA is complementary to at least 8 nucleotides of each of the at least two DNA polynucleotide sequences.

15. The method of claim 1 , wherein the detecting is quantitative.

16. The method of claim 1 , wherein the ligase that has an amino acid sequence that is at least 95% identical to the Chlorella virus PBCV-1 ligase of SEQ ID NO:1.

Assignments (3)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2023
From: LOHMAN, GREGORY; EVANS, THOMAS C., JR.; MCREYNOLDS, LARRY A.
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 064561/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2015
From: LOHMAN, GREGORY; EVANS, THOMAS C., JR.; MCREYNOLDS, LARRY A.
To: NEW ENGLAND BIOLABS
Reel/Frame 036566/0943 →